Medical imaging: a comprehensive product range
Our portfolio contains solutions for Diagnostic Imaging (CT/Cath Lab, MRI, injectors, medical devices, softwares and services) and for Interventional Imaging (Contrast agents and medical devices).
Patient diagnostics: 36 million doses manufactured in 2017
More than 60,000 health professionals rely on our contrast agents to diagnose disease and assess treatment efficacy.
More than 200 employees devoted to R&D
Advancing in innovation solutions, the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system) and interventional radiology while reconciling efficacy and cost containment, are at the heart of Guerbet's mission. In 10 years, the Group spent €393M in R&D.
Involvement in more than 100 R&D partnerships
With its worldwide network of scientific partners in both the public and private sectors, Guerbet is fueling progress in imaging technologies.
Lipiodol®, the pioneering contrast agent
First discovered in 1901, Lipiodol® in 1921 became the first iodized contrast agent to be used in radiology. It serves today in interventional imaging.
2,700 employees and a worldwide presence
Our products and services are made available in more than 80 countries through our affiliates and network of distributors.
Turnover of €807.1m in 2017
Guerbet is reporting revenue of €807.1 million at December 31, 2017, up by 4.0% at current exchange rates. This growth includes a negative exchange rate effect* of €5.3 million over the year. At constant exchange rates, revenue therefore rose by 4.7% to €812.4 million, beating the target of 3% to 4% announced on September 30.
9 specialized manufacturing plants
Guerbet has acquired the facilities necessary for high-performance industrial production: 3 sites for the manufacture of the active pharmaceutical ingredients (APIs), 4 fill-and-finish facilities for our contrast agents, and 2 sites dedicated to imaging solutions (injectors, disposables) and services.
Dotarem® leader in Europe
Used for 29 years in clinical practice, more than 75 million* doses of Dotarem® have been injected in the world.
*Data December 2017